Background-Limited long-term data exist on patients who have undergone drug-eluting stenting of very long lesions (requiring Ն60 mm of continuous stent) in native coronary arteries ("full-metal jacket"). Methods and Results-We examined consecutive procedures taking place between March 2002 and 2007 at 2 high-volume centers in Milan, Italy. Exclusion criteria were percutaneous coronary intervention for restenosis, percutaneous coronary intervention to a bypass graft, or percutaneous coronary intervention for acute ST-elevation myocardial infarction (MI). We identified 658 full-metal jacket lesions in 617 patients. Average age of the cohort was 62.0Ϯ10.6; 32.8% were diabetic, 51.5% had a previous MI, and 33.4% had undergone a previous percutaneous transluminal coronary angioplasty. Mean ejection fraction was 52.1Ϯ10.4%. The lesion was a chronic total occlusion in 33.0%. Median duration of clinical follow-up was 39 months (interquartile range, 28 to 50). Six-month follow-up was achieved in 97% of patients; 2-year follow-up was achieved in 91%. All-cause mortality rate was 7.3%; cardiac death rate was 3.6%. Non-procedure-related MI rates were 3.5%. Target lesion revascularization rates were 23.4%. There were 17 cases of Academic Research Consortium-defined definite or probable stent thrombosis (2.6%): 5 acute, 2 subacute, 6 late, and 4 very late. Ten of the 17 cases occurred while the patient was receiving dual antiplatelet therapy; 4 of the 17 after premature termination of 1 or both antiplatelets, and 3 of the 17 occurred while the patient was receiving single-antiplatelet therapy, after having completed the prescribed course of dual antiplatelet therapy. Conclusion-When very long lesions (Ն60 mm) were treated using overlapping drug-eluting stents, 23.4% required a further procedure for restenosis at 3-year follow-up. However, MI, stent thrombosis, and cardiac mortality rates were relatively low. (Circ Cardiovasc Intervent. 2009;2:416-422.)
T he advent of drug-eluting stents (DES) has allowed interventional cardiologists to tackle longer lesions with reduced rates of restenosis compared with those for baremetal stents or plain old balloon angioplasty. 1, 2 However, even when using DES, target lesion revascularization remains a significant issue, particularly in complex lesions where very long segments of stenting may be required. [3] [4] [5] [6] 
Clinical Perspective on p 422
Procedural "full-metal jackets" (FMJs), defined for the purposes of this study as a continuous segment of stenting measuring 60 mm or more, is something that cardiologists frequently avoid for fear of adverse long-term consequences. However, there are relatively few data in the literature regarding the long-term follow-up of FMJ procedures and, in particular, the long-term risk of stent thrombosis (ST) remains unknown.
Therefore, we followed up a large cohort of FMJ procedures to establish the frequency of adverse events in a population receiving DES.
Methods
We examined all procedures taking place between March 2002 and March 2007 at 2 high-volume centers in Milan, Italy. Each procedure was entered into a percutaneous coronary intervention (PCI) database at the time of the procedure by the operator, and subsequently, all clinical parameters were validated through a case record inspection.
The 2 databases combined contained 45 060 individual lesion PCI procedures (Figure 1 ). Of these, 9143 lesions were treated with DES within the time period of interest. Exclusion criteria were PCI for restenosis, PCI to a bypass graft, or PCI for acute ST-elevation myocardial infarction (MI). All other patients receiving 60 mm of overlapping drug eluting to a single vessel were included. To validate the identification of FMJ procedures, each procedure was individually inspected to ensure that stents did indeed overlap. Furthermore, all other procedures involving the requisite length of stent were examined to ensure that we did not miss any potential cases.
Using these criteria, 658 individual FMJ lesion procedures were identified in 617 patients and form the basis of this study.
All patients provided informed consent for both the procedure and subsequent data collection and analysis for research purposes. Procedural antiplatelet therapy and heparin dosing followed standard protocols. 7 Platelet glycoprotein IIb and IIIa receptor inhibitors, interventional approach, and intravascular ultrasound usage were at the operator's discretion.
Stent implantation occurred according to standard techniques, with the choice of DES left to the discretion of the operator (in our centers, this included sirolimus-, paclitaxel-, zotarolimus-, and everolimus-eluting stents). Protection of side branches was encouraged, with "jailing" of wires as required. A degree of overlap between stents was required, but the degree of overlap was intentionally minimized. Postdilatation strategy was left to the discretion of the operator.
A procedure was coded as a major bifurcation if the overlapping stents covered a side branch visually estimated to be Ͼ2 mm in diameter by the operator. A chronic total occlusion (CTO) was defined as an artery occluded for Ͼ3 months with Thrombolysis in Myocardial Infarction grade 0 flow at the start of the procedure.
Clinical Follow-Up
Clinical follow-up was attempted on all subjects by clinic visit or by telephone interview. The results reported represent lesion-specific (device-specific) data. This means that any clinical event proven to occur as result of a non-FMJ vessel was disregarded. Where doubt occurred, the event was coded as being due to the FMJ vessel.
Periprocedural MI was defined according to the universal definition of MI as a creatine kinase-MB level Ͼ3 times the upper limit of the normal range, occurring within the first 24 hours postprocedure. 8 Out-of-hospital MI was defined as a creatine kinase level of Ͼ3 times the upper limit of normal with a positive creatine kinase-MB in the context of an appropriate history or electrographic changes. When out-of-hospital MI was diagnosed clinically, it was coded as an FMJ-related MI unless coronary angiography demonstrated an acute occlusion within a non-FMJ vessel during the same hospital admission. Where angiography was not performed, or there was doubt on angiography as to the culprit vessel, the event was coded as an FMJ-related MI. All deaths were coded as cardiac in nature unless a noncardiac cause was clearly proven.
Angiographic restenosis was defined as a luminal stenosis of Ͼ50% within the treated segment, or within 5 mm of the treated segment, and was calculated by a dedicated team of researchers using computer-assisted quantitative coronary angiography technology. Restenosis was coded as focal (Յ10 mm), diffuse (Ͼ10 mm), or occlusive. Target lesion revascularization was defined as surgical, or percutaneous, intervention to the previously stented area, or 5 mm proximal or distal to the stent. Repeat intervention to the target vessel in any other area from that defined by target lesion revascularization (TLR) was considered to be target vessel revascularization.
ST was coded according to the Academic Research Consortium definitions of definite, probable, and possible. 9 In accordance with this definition, the temporal distribution of ST was defined as acute (occurring within the first 24 hours), subacute (between 1 and 30 days), late (between 30 days and 1 year), or very late (after 1 year).
Statistical Analysis
Normally distributed data are quoted as meanϮSD; nonparametric data are quoted as medianϮinterquartile range. Categorical data are reported as number followed by percentage incidence. Continuous variables were compared with Student t test or Wilcoxon ranked scores, whereas the Fisher exact test (where there were Ͻ10 events per cell) or 2 test was used for categorical variables when appropriate. The cumulative incidence of adverse events was calculated according to the Kaplan-Meier method, and the Kaplan-Meier curves reported end points that were censored at the time of first event or at 1000 days, whichever occurred first.
Predictors of clinical outcomes were identified using multivariate Cox regression models, containing factors demonstrated on univariate analysis to predict the frequency of the event outcome (at a significance level of PϽ0.05) and factors previously associated with the event outcome in the literature. A 2-sided P value of Ͻ0.05 was considered statistically significant. Statistical analysis was performed using SPSS version 16.0 (SPSS, Inc, Chicago, Ill).
Results
Demographic data are contained in Table 1 . This was a complex cohort of patients, with an average age of 62.0Ϯ10.6 years, of whom 32.8% were diabetic, 51.5% had a previous MI, 64.7% had been treated for hyperlipidemia, 70.2% had hypertension, and 33.4% had previously had percutaneous transluminal coronary angioplasty. Mean ejection fraction (EF) was 52.1Ϯ10.4%.
Procedural characteristics are contained in Table 2 . Mean length of stent used to treat the FMJ lesions was 77.8Ϯ18.4 mm (range, 60 to 118). Final maximal balloon diameter used was 3.1Ϯ0.4 mm. The lesion treated was a CTO in 33.0% and involved a major bifurcation in 11.4% of cases. A glycoprotein IIb/IIIa inhibitor was used in 27.2% of patients. The FMJ vessel was treated as part of a multivessel 
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procedure in 50.5% of cases, and the target vessel was most often the left anterior descending (43.5%) or the right coronary artery (43.5%).
Most of the cases were done using either a sirolimuseluting (59.9%) or a paclitaxel-eluting stent (35.3%); half of the procedures involved an ostial or proximal vessel location.
Clinical Follow-Up
Median clinical follow-up on the cohort was 38.9 months (interquartile range, 27.5 to 49.5). Six-month follow-up was achieved in 97% of patients, and 2-year follow-up was achieved in 91%. All-cause mortality rate was 7.3%; cardiac death occurred in 3.6% of subjects ( Table 3) .
The procedure-related MI rate for single-vessel FMJ procedures (326 lesions) was 9.5% and as part of a multivessel procedure (332 lesions) was 19.0%. Nonprocedure-related MI rates were 3.5%. Overall cardiac death/MI rate was 6.1%. Figure 2 shows a Kaplan-Meier survival curve for freedom from cardiac death/non-procedurerelated MI at 1000 days.
The recommendations for duration of dual antiplatelet therapy (DAT) made at the time of the PCI procedure and the subsequent compliance rates are contained in Table 4 . More than 95% of patients received 6 months of DAT.
There were 17 cases of Academic Research Consortium definite or probable ST (2.6%). Five were acute, 2 subacute, 6 late, and 4 very late. Median time to event for these subjects was 5.0 months (interquartile range, 0.03 to 15.4). Ten of the 17 cases occurred while patients were on DAT; 4 of the 17 occurred after premature termination of 1 or both antiplatelets because of new gastrointestinal pathology (gastritis, hyperemesis, pancreatitis, and gastrointestinal bleeding; mean time from cessation of DAT to ST was 5.25 days). The remaining 3 cases occurred while patients were on singleantiplatelet therapy after having completed the 12-month prescribed course of DAT; these occurred at 21, 22, and 74 months postprocedure. There were a further 12 cases of possible ST (median time to event, 32.8 months; interquartile range, 17.4 to 39.6).
Target lesion revascularization rates were 23.4%; target vessel revascularization rates were 27.8%. Combined cardiac death/MI/TLR rates were therefore 26.1%. Figure 3 demonstrates a Kaplan-Meier curve showing freedom from cardiac death/MI/TLR at 1000 days.
Angiographic follow-up was performed in 72.6% of lesions. Restenosis type was focal in 89 lesions (60.1%), diffuse in 29 lesions (19.6%), and occlusive in 30 lesions (20.3%).
Multivariate Analysis
We initially examined the combined end point of cardiac death/non-procedure-related MI against age, gender, diabetes, EF, heavy angiographic calcification, smoking status, length of stent, glycoprotein IIb/IIIa use, final maximum balloon diameter used, and final maximum balloon atmospheres (Tables 5 and 6 ). The only significant univariate predictor of outcome was EF (mean EF for events, 46.6%, versus nonevents, 52.5%; PϽ0.001). In a Cox regression model containing EF, diabetes, age, length of stent, and final maximum balloon diameter used, this remained significant (hazard ratio [HR], 0.96; CI, 0.94 to 0.98; Pϭ0.001) and diabetes strengthened to achieve significance (HR, 2.24; CI, 1.16 to 4.33; Pϭ0.02). 
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We then examined predictors of definite/probable/possible ST by a univariate analysis, using age, gender, diabetes, smoking, heavy angiographic calcification, EF, bifurcation procedure, CTO procedure glycoprotein IIb/IIIa use, length of stent, maximal balloon diameter, and premature discontinuation of DAT. Premature DAT discontinuation was the only significant predictor of outcome (ST rate for no premature discontinuation 4% versus 11.4% for those with premature discontinuation; Pϭ0.04).
This weakened to a nonsignificant relationship after adjustment for diabetes and EF within a Cox regression model (HR, 2.31 for ST with premature discontinuation of DAT; CI, 0.79 to 6.82; Pϭ0.13). Because there were only 29 events of interest, we were unable to adjust for any further covariates within the same model, although rotating length of stent and maximal balloon diameter used, for EF, did not change the outcome (data not shown).
Finally, factors predicting TLR were examined. On univariate analysis, only maximal balloon diameter used (TLR, 3.00 mm, versus no-TLR, 3.16 mm; PϽ0.001), and diabetes (TLR rate for diabetes, 30.0%, versus 20.0% for no diabetes; Pϭ0.005) significantly predicted the outcome, whereas age, gender, bifurcation procedure, CTO procedure, heavy angiographic calcification, total length of stent, final maximum balloon atmospheres used, cutting balloon use, intravascular ultrasound use, and rotablator use did not predict outcomes. In a Cox regression model containing diabetes, length of stent, maximal balloon size used, and CTO procedure, the most powerful predictors of TLR remained final maximum balloon size used (HR, 0.47; CI, 0.30 to 0.72; PϽ0.001) and diabetes (HR, 1.81; CI, 1.31 to 2.51; PϽ0.001).
Recanalization of a CTO with subsequent FMJ was not associated with TLR on univariate analysis (CTO procedure TLR rate 23.3% versus non-CTO procedure 23.5% Pϭ0.97). This did not change after adjustment for age, gender, diabetes, length of stent, and maximal balloon size used (Pϭ0.25). Similarly, there was no association on univariate analysis between CTO procedure and ST (Pϭ0.40), which did not change after adjustment for cofactors.
Discussion
The principal findings of this study are (1) periprocedural MI rates for single-vessel FMJ of 9.5%; (2) out-of-hospital MI rates of 3.5% at a median follow-up time of 38.9 months; (3) cardiac death rates of 3.6%; (4) definite or probable ST rates of 2.6%; and (5) TLR rates of 23.4%.
This study details, to our knowledge, the largest cohort of FMJ procedures published to date with the longest reported duration of clinical follow-up. Before this study, the largest series reporting outcomes from FMJ procedures was published in 2006 by Lee et al. 10 They detailed outcomes on 347 FMJ patients at 16 months; reporting 6 cardiac deaths (1.7%), 1 nonfatal MI (0.3%), and 13 target lesion revascularizations (3.8%). A smaller cohort from Aoki et al 11 also reported outcomes in 122 procedures, with slightly shorter clinical follow-up (1 year). In that cohort, there were 5 deaths (4.1%), 10 MIs (8.2%), and a 7.5% target vessel revascularization rate. Two additional case series have also reported outcomes on 88 and 66 patients, respectively. 12, 13 We are therefore able to significantly extend these findings and provide some reassurance regarding longer-term outcomes, particularly with respect to ST. Our overall rate of definite or probable ST was 2.6%. Ten of these 17 events (1.6%) occurred after 30 days, with only 4 of these patients having very late thrombosis (after 1 year). An important factor to note when considering the implications of these findings, however, is that as a result of the significant length of stent implanted, 40% of the patients in this cohort were prescribed long-term DAT on empirical grounds. Furthermore, there were 12 cases of possible ST (6 taking DAT at the time) with a median time to event of 33 months. Even with these factors, however, an overall 3-year cardiac mortality of 3.6% is reassuring.
A limitation of treating diffuse coronary disease with long sections of stent is the high incidence of periprocedural MI. Rates were 19.6% in the series from Lee et al and 4.0% in the series from Aoki et al. In our study, rates were 9.5% for single-vessel procedures and 19.0% for multivessel procedures (ie, an FMJ procedure plus any other PCI at the same procedure), which are not unduly high compared with historical cohorts undergoing stent implantation, 14 especially given that 43.5% of the current cohort underwent PCI to the left anterior descending artery. The significance of any periprocedural enzymes rise remains a topic of some debate, 15, 16 but it is somewhat reassuring that FMJ procedures are not associated with excessively high rates of MI in our cohort.
Although the TLR rate was significant (23.4%), it is worth noting how many of these patients exhibited only focal restenosis (60%). It is also notable that only 30 of the 154 cases of TLR subsequently required a third procedure (4.6% of whole cohort, 19.4% of TLR cases). Given that the index procedure in all of these cases represents a reconstruction of a major epicardial vessel, this gives us some reassurance that, although a second procedure may be necessary, the nature of the lesion treated in that second procedure is frequently different from that of the first (a "tidy-up procedure"), and the subsequent need for further invasive treatment is low. As with previous studies reporting outcomes using DES, we saw a peak in TLR between 6 and 12 months, before observing a decline in TLR rates. The most powerful predictor of cardiac death or MI identified was EF, a pattern also identified in the cohort of patients from Lee et al. Diabetes trended toward prediction on univariate analysis (Pϭ0.06) and this strengthened a little in the multivariate model (Pϭ0.02). The only factor predictive of ST on a univariate analysis was premature discontinuation of antiplatelet therapy, a previously well-recognized risk factor 17 ; however, this weakened to a trend after adjustment (Pϭ0.13). The relatively small number of events within this study limits our ability to rule out other potential predisposing factors for events. Longer follow-up or more adverse events may have identified other associative factors.
Target lesion revascularization was strongly predicted by vessel diameter (examined through the surrogate marker of final maximum balloon size used) and diabetes. However, interestingly, total length of stent was not. Given the large body of data in existence linking length of stented area to restenosis, this is an interesting finding. 18 -20 Whether a threshold effect exists, whereupon length of stent no longer strongly affects restenosis, is one possible explanation requiring further study.
Finally, the TLR rates for CTO versus non-CTO lesions were found to be similar (CTO 23.3% versus non-CTO 23.5%; Pϭ0.97) within this cohort, and this did not change after adjustment for potential confounding factors (Pϭ0.25). This raises the possibility that long CTO lesions may not necessarily lead to higher rates of restenosis when compared with very long nonocclusive lesions. When considered separately, clinicians tend to associate both long CTO lesions and FMJ procedures with high rates of restenosis 21, 22 ; however, until now, there has not been a cohort of these patients large enough to allow meaningful comparison of very long CTO lesions and very long non-CTO lesions. In addition, ST rates were unaffected by the presence or absence of a CTO lesion, although numbers of definite/probable ST were low, and this study lacked the number of end points to test this concept rigorously.
Study Limitations
This is a retrospective study of PCI procedures performed and therefore is inherently prone to bias. Procedures most associated with risk in the minds of the operator may have been avoided, and therefore, the data presented here may represent a lower risk cohort of FMJ lesions compared with the cross-section of such cases seen. As a result, extrapolating these data to any FMJ procedure is not advised; rather, these data should be considered to represent the results of all cases performed at our 2 centers. Second, although safety data appear reasonable, the operators advised prolonged DAT in a significant number of cases, which may have implications in a more cost-restrictive environment or in those at higher bleeding risk than this cohort.
Conclusion
In this large cohort of FMJ procedures, we report low rates of cardiac death, ST, and MI at 3-year follow-up. Target lesion revascularization rates were high at 23%; however, in the majority of these cases, the affected area exhibited mainly focal restenosis. The ST rate was 2.6% at a median follow-up time of 39 months, with 60% of patients having stopped dual-antiplatelet therapy at 1 year.
